SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort
J Neurol
.
2022 Mar;269(3):1133-1137.
doi: 10.1007/s00415-021-10818-w.
Epub 2021 Oct 5.
Authors
Katharina Eisenhut
1
2
,
Stefan Buchka
3
4
,
Peter Eichhorn
5
,
Harald Meier
4
6
,
Fady Albashiti
4
6
,
Ulrich Mansmann
3
4
,
Miriam Schlüter
1
2
,
Joachim Havla
#
1
2
4
,
Tania Kümpfel
#
7
8
Affiliations
1
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
2
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
3
Institute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, LMU Munich, Munich, Germany.
4
Data Integration for Future Medicine (DIFUTURE) Consortium, LMU Munich, Munich, Germany.
5
Institute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany.
6
Medical Technology and IT (MIT), University Hospital, LMU Munich, Munich, Germany.
7
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
[email protected]
.
8
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
[email protected]
.
#
Contributed equally.
PMID:
34609601
PMCID:
PMC8491170
DOI:
10.1007/s00415-021-10818-w
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Viral
COVID-19*
Cohort Studies
Humans
SARS-CoV-2*
Seroepidemiologic Studies
Substances
Antibodies, Viral
Grants and funding
01ZZ1603[A-D]/bundesministerium für bildung und forschung
01ZZ1804[A-H] (DIFUTURE)/bundesministerium für bildung und forschung